Tyme Announces Encouraging Efficacy and Safety Data from First Human Study of SM-88 in Women with Metastatic Breast Cancer
November 06, 2017 08:00 ET
|
Tyme Technologies, Inc.
Median overall survival of 35 months in 14 progressive metastatic breast cancer patients despite multiple lines of prior therapy (average 2.5 lines of systemic drug therapy prior to SM-88)43 percent...
Tyme to Announce Second Quarter Fiscal Year 2017 Operational Update and Schedules Investor Conference Call
November 03, 2017 08:30 ET
|
Tyme Technologies, Inc.
NEW YORK, Nov. 03, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, announced...
Tyme Identifies Potential Method and Biomarker for Converting Malignant Tumors to Inert Calcified Mass
October 25, 2017 08:00 ET
|
Tyme Technologies, Inc.
Mechanism for conversion works in conjunction with SM-88’s core technologyConfirmed ability to calcify osteosarcoma tumors in canine models Identified biomarker appears to have applicability to a...
Tyme’s SM-88 Demonstrates Prolonged Overall Survival in Metastatic Cancer Patients Across Multiple Subgroups
October 19, 2017 08:30 ET
|
Tyme Technologies, Inc.
Patients receiving no subsequent therapy experienced a longer median overall survival (OS) than patients who received subsequent treatments beyond SM-88Patients with two or more prior systemic...
Tyme Adds Distinguished Drug Developer, Briggs W. Morrison, M.D. to Advisory Board
September 14, 2017 08:30 ET
|
Tyme Technologies Inc
NEW YORK, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today...
TYME Presentation at ESMO Reported 100% of Current Prostate Cancer Patients Have Demonstrated a Reduction in Circulating Tumor Cells, Most Becoming Undetectable
September 11, 2017 08:30 ET
|
Tyme Technologies Inc
- Results suggest SM-88 may help avoid or delay more intensive treatments, such as chemical castration, in prostate cancer patients - - All subjects receiving study drug had radiographic progression...
Tyme’s Updated Long-Term Analysis Shows 29-Month Median Overall Survival in Metastatic Cancer Patients that Achieved Stable Disease
September 07, 2017 09:02 ET
|
Tyme Technologies Inc
- Stable disease patient group had failed a median of two prior lines of therapy and entered the trial with progressive metastatic disease - - Analysis suggests traditional RECIST response criteria...
Tyme Technologies, Inc. to Present at Upcoming Investor Conferences
August 30, 2017 08:30 ET
|
Tyme Technologies Inc
NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that Ben...
Tyme Inc. to Present Prostate Cancer Data from its Ongoing Phase II Trial for SM-88 at ESMO 2017
August 29, 2017 08:31 ET
|
Tyme Technologies Inc
NEW YORK, Aug. 29, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced that it...
Tyme Technologies, Inc. Announces the Issuance of Two New Platform Patents
August 14, 2017 08:30 ET
|
Tyme Technologies Inc
NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Tyme Inc. (Nasdaq:TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, announced the United...